AMPLY Discovery
AMPLY Discovery is a biotech company leveraging AI and evolutionary biology to discover novel medicines, focusing on cancer and infectious diseases. Their proprietary AMPLYfolio AI platform digitizes biological diversity using next-generation sequencing and applies advanced machine learning to identify novel drug candidates, which are then bio-printed and validated in leading hospital labs. The company targets genetically-mediated cancers and drug-resistant infections, aiming to out-license validated drug candidates to larger biopharma partners. AMPLY Discovery has secured nearly $3 million in funding and is recognized in industry reports and innovation programs, positioning itself as a cutting-edge drug discovery studio addressing major global health challenges.
AMPLY Discovery
AMPLY Discovery is a biotech company leveraging AI and evolutionary biology to discover novel medicines, focusing on cancer and infectious diseases. Their proprietary AMPLYfolio AI platform digitizes biological diversity using next-generation sequencing and applies advanced machine learning to identify novel drug candidates, which are then bio-printed and validated in leading hospital labs. The company targets genetically-mediated cancers and drug-resistant infections, aiming to out-license validated drug candidates to larger biopharma partners. AMPLY Discovery has secured nearly $3 million in funding and is recognized in industry reports and innovation programs, positioning itself as a cutting-edge drug discovery studio addressing major global health challenges.
TL;DR
Headquarters: Belfast, United Kingdom
Focus: AI-driven drug discovery for cancer and infectious diseases
Proprietary platform: AMPLYfolio AI (digitizes biological diversity, links in silico discovery to bioprinting and lab validation)
Founded: 2021
Early funding: Seed + grants (reported ~£2.3M rounds and ~ $3M combined funding/grants)
Founding management includes Dr Ben Thomas (CEO/CTO) and Dermot Tierney (CFO/CCO)
Company Overview
Problem Domain
Drug discovery for cancer and infectious diseases; discovery of novel biologics from natural sequence diversity.
Founded
2021
Industry
Biotechnology
Funding Track Record
£900,000
Reported QUB spin-out funding event
£1,400,000
Reported funding round for AI drug discovery platform
5228537
Aggregated funding figure reported in company snapshot (currency USD)
Investor Signal
“Seed round led by Twin Path Ventures; other reported investors include QUBIS, Co-FundNI and British Business Bank”